You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

VYTORIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Vytorin patents expire, and what generic alternatives are available?

Vytorin is a drug marketed by Organon and is included in one NDA.

The generic ingredient in VYTORIN is ezetimibe; simvastatin. There are twenty-four drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the ezetimibe; simvastatin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Vytorin

A generic version of VYTORIN was approved as ezetimibe; simvastatin by DR REDDYS LABS SA on April 26th, 2017.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VYTORIN?
  • What are the global sales for VYTORIN?
  • What is Average Wholesale Price for VYTORIN?
Drug patent expirations by year for VYTORIN
Drug Prices for VYTORIN

See drug prices for VYTORIN

Drug Sales Revenue Trends for VYTORIN

See drug sales revenues for VYTORIN

Recent Clinical Trials for VYTORIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Samsung Medical CenterPhase 4
Cairo UniversityN/A
Aswan Heart CentreN/A

See all VYTORIN clinical trials

Paragraph IV (Patent) Challenges for VYTORIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VYTORIN Tablets ezetimibe; simvastatin 10 mg/10 mg 10 mg/20 mg 10 mg/40 mg 10 mg/80 mg 021687 1 2009-07-27

US Patents and Regulatory Information for VYTORIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-001 Jul 23, 2004 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Organon VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-004 Jul 23, 2004 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Organon VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-002 Jul 23, 2004 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Organon VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-003 Jul 23, 2004 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VYTORIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-001 Jul 23, 2004 ⤷  Sign Up ⤷  Sign Up
Organon VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-003 Jul 23, 2004 ⤷  Sign Up ⤷  Sign Up
Organon VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-001 Jul 23, 2004 ⤷  Sign Up ⤷  Sign Up
Organon VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-004 Jul 23, 2004 ⤷  Sign Up ⤷  Sign Up
Organon VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-003 Jul 23, 2004 ⤷  Sign Up ⤷  Sign Up
Organon VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-004 Jul 23, 2004 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VYTORIN

See the table below for patents covering VYTORIN around the world.

Country Patent Number Title Estimated Expiration
Taiwan 200412944 Pharmaceutical formulation ⤷  Sign Up
Portugal 1531805 ⤷  Sign Up
Argentina 040588 FORMULACION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE LA ABSORCION DEL COLESTEROL Y UN INHIBIDOR DE UNA HMG- CO A REDUCTASA ⤷  Sign Up
Australia 2009200768 Composition comprising a cholesterol absorption inhibitor, an HMG-CoA reductase inhibitor and a stabilizing agent ⤷  Sign Up
Ecuador SP941119 COMPUESTOS ANTIHIPERCOLESTEROLEMICOS ⤷  Sign Up
Japan S56122375 NOVEL ANTIHYPERCHOLESTEREMIC COMPOUND* ITS INTERMEDIATE AND ITS MANUFACTURE ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VYTORIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0720599 05C0040 France ⤷  Sign Up PRODUCT NAME: EZETIMIBE; SIMVASTATINE; NAT. REGISTRATION NO/DATE: NL 31849 20050728; FIRST REGISTRATION: DE - 58 878 00 00 20040402
0720599 C00720599/02 Switzerland ⤷  Sign Up FORMER OWNER: SCHERING CORPORATION, US
0720599 03C0028 France ⤷  Sign Up PRODUCT NAME: EZETIMIBE; NAT. REGISTRATION NO/DATE: NL28237 20030611; FIRST REGISTRATION: DE - 54486.00.00 A 54489.00.00 20021017
0720599 SPC/GB05/010 United Kingdom ⤷  Sign Up PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411
0720599 300688 Netherlands ⤷  Sign Up PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NATIONAL REGISTRATION NO/DATE: RVG114002-004 20140811; FIRST REGISTRATION: NO 13-9663 - 9665 20140724
0720599 20/2003 Austria ⤷  Sign Up PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; NAT. REGISTRATION NO/DATE: 1-24902 1-24904 20030415; FIRST REGISTRATION: DE 54486.00.00 - 54489.00.00 20021017
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.